Phase 3 Readout~month

Phase 3 Topline: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phas

Drug
maci
Indication
Chondral Defect; Articular Cartilage Defect

Other upcoming events for VCEL

Patent ExpiryPatent/Exclusivity Expiry: MACRILEN
Patent ExpiryPatent/Exclusivity Expiry: OPSUMIT
Patent ExpiryPatent/Exclusivity Expiry: OPSYNVI
Patent ExpiryPatent/Exclusivity Expiry: VERZENIO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phas — VCEL Phase 3 Readout | BioSniper